Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page
- Check5 days agoChange DetectedThe page's revision metadata was updated from v3.6.4 to v3.6.5, indicating a minor update to the page's revision number.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision tag was updated to v3.6.4, indicating a minor update to the ClinicalTrials.gov record. No study data or criteria appear to be altered.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe study's recruitment status was updated to 'Active, not recruiting' with a note that no participants are being sought, indicating enrollment has closed. Several investigator and contact details were removed, reducing publicly listed study contacts.SummaryDifference4%

- Check41 days agoChange DetectedThe page revision label updated from v3.6.2 to v3.6.3, indicating a new version of the page or its underlying system. This update does not alter the study details or other content presented.SummaryDifference0.0%

- Check48 days agoChange DetectedA new page revision tag v3.6.2 was added and the previous v3.6.0 tag removed, indicating a minor update to the page's revision history.SummaryDifference0.0%

- Check62 days agoChange DetectedNew navigation/help items were added, including Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, and How to Join a Study, and the Intervention/Treatment heading was standardized (Intervention / Treatment vs Intervention/Treatment). The page revision tag was updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.